Journal article icon

Journal article

Ruxolitinib versus best available therapy for ET intolerant or resistant to hydroxycarbamide in a randomized trial

Abstract:

Treatments for high-risk essential thrombocythemia (ET) address thrombocytosis, disease-related symptoms, as well as risks of thrombosis, hemorrhage, transformation to myelofibrosis and leukemia. Patients resistant/intolerant to hydroxycarbamide (HC) have a poor outlook. MAJIC (ISRCTN61925716) is a randomized phase II trial of ruxolitinib (JAK1/2 inhibitor) vs Best Available Therapy (BAT) in ET and polycythemia vera (PV) patients resistant or intolerant to HC. Here findings of MAJIC-ET are...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted manuscript

Actions


Access Document


Files:
Publisher copy:
10.1182/blood-2017-05-785790

Authors


More by this author
Department:
Oxford, MSD, RDM, RDM Clinical Laboratory Sciences
Role:
Author
Expand authors...
More from this funder
Grant:
Trials Acceleration Program
Publisher:
American Society of Hematology Publisher's website
Journal:
Blood Journal website
Volume:
130
Issue:
17
Pages:
1889-1897
Publication date:
2017-08-09
Acceptance date:
2017-07-24
DOI:
EISSN:
1528-0020
ISSN:
0006-4971
Pubs id:
pubs:725712
URN:
uri:e34431b4-d012-413f-80b7-afd083002a97
UUID:
uuid:e34431b4-d012-413f-80b7-afd083002a97
Local pid:
pubs:725712

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP